百克生物：获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Baike Biotech has received approval from the National Medical Products Administration for a clinical trial of its combined vaccine for adults and adolescents [1] - Baike Biotech's revenue composition for the year 2024 is entirely from biopharmaceuticals, accounting for 100% [2] - As of the latest update, Baike Biotech has a market capitalization of 9.6 billion yuan [3]